PMID- 21629292
OWN - NLM
STAT- MEDLINE
DCOM- 20110802
LR  - 20220419
IS  - 1474-1784 (Electronic)
IS  - 1474-1776 (Linking)
VI  - 10
IP  - 6
DP  - 2011 Jun
TI  - Principles and mechanisms of vessel normalization for cancer and other angiogenic 
      diseases.
PG  - 417-27
LID - 10.1038/nrd3455 [doi]
AB  - Despite having an abundant number of vessels, tumours are usually hypoxic and 
      nutrient-deprived because their vessels malfunction. Such abnormal milieu can 
      fuel disease progression and resistance to treatment. Traditional 
      anti-angiogenesis strategies attempt to reduce the tumour vascular supply, but 
      their success is restricted by insufficient efficacy or development of 
      resistance. Preclinical and initial clinical evidence reveal that normalization 
      of the vascular abnormalities is emerging as a complementary therapeutic paradigm 
      for cancer and other vascular disorders, which affect more than half a billion 
      people worldwide. Here, we discuss the mechanisms, benefits, limitations and 
      possible clinical translation of vessel normalization for cancer and other 
      angiogenic disorders.
FAU - Carmeliet, Peter
AU  - Carmeliet P
AD  - Vesalius Research Center, VIB, K. U. Leuven, Campus Gasthuisberg, Herestraat 49, 
      B-3000 Leuven, Belgium. peter.carmeliet@vib-kuleuven.be
FAU - Jain, Rakesh K
AU  - Jain RK
LA  - eng
GR  - P01-CA80124/CA/NCI NIH HHS/United States
GR  - R01-CA115767/CA/NCI NIH HHS/United States
GR  - R01-CA126642/CA/NCI NIH HHS/United States
GR  - R01-CA85140/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
PL  - England
TA  - Nat Rev Drug Discov
JT  - Nature reviews. Drug discovery
JID - 101124171
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Angiogenesis Inhibitors/metabolism/*therapeutic use
MH  - Animals
MH  - Antineoplastic Agents/metabolism/therapeutic use
MH  - Humans
MH  - Neoplasms/drug therapy/metabolism/*physiopathology
MH  - Neovascularization, Pathologic/drug therapy/metabolism/*physiopathology
MH  - Vascular Endothelial Growth Factor A/metabolism
EDAT- 2011/06/02 06:00
MHDA- 2011/08/04 06:00
CRDT- 2011/06/02 06:00
PHST- 2011/06/02 06:00 [entrez]
PHST- 2011/06/02 06:00 [pubmed]
PHST- 2011/08/04 06:00 [medline]
AID - nrd3455 [pii]
AID - 10.1038/nrd3455 [doi]
PST - ppublish
SO  - Nat Rev Drug Discov. 2011 Jun;10(6):417-27. doi: 10.1038/nrd3455.